("Incanthera" or the "Company")
Designation into new Apex market of the
The AQSE Growth Market will be divided into two segments in order to provide appropriate support across companies' growth cycles. Apex is the intended market for larger, more established businesses.
The changes have been developed to enhance
Incanthera is delighted to have met the criteria for Apex companies.
The Apex market brings a number of advantages to Incanthera, including:
· Protection from short selling by third parties
· A market maker incentive scheme, designed to increase liquidity on the exchange
Incanthera was successfully floated on AQSE in February this year.
Incanthera is focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.
Commenting on the changes coming into effect, Tim McCarthy, Chairman, said:
"We are delighted to have been designated into the new Apex market of
The support we have received from Aquis as one of the growth businesses on the Exchange has been extremely important to us and we applaud the team for these further initiatives to support the stocks listed on the Exchange.We expect that this will bring many benefits to Incanthera's existing shareholders, whilst also attracting new investors to the Aquis market."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
The Directors of Incanthera accept responsibility for this announcement.
For further information, please contact:
Tim McCarthy, Chairman +44 (0) 7831 675747
Simon Ward, Chief Executive Officer +44 (0) 7747 625506
Suzanne Brocks, Head of Communications +44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Jo Turner/James Lewis
Patrick Claridge/John Howes/Bob Pountney
Notes to Editors
Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.
The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.
The Company originated from the
The majority of conventional cancer treatments (other than surgery) on the market are chemotherapy or radiotherapy based. These are non-selective by nature and highly toxic to healthy tissue as well as tumours. Accordingly, treatment can only be delivered in carefully controlled doses over a limited period of time. To address this problem directly, the Company has developed sophisticated formulation and prodrug targeting technologies to deliver treatment specifically to the tumour. Prodrugs are chemically modified versions of pharmacologically active agents which only become active when they reach a target, thus reducing generalised toxicity in normal tissues, whilst enabling higher doses to reach a target and therefore increase efficacy.
Incanthera's Board and management possess a broad range of commercial, scientific and public company experience. In addition, Incanthera benefits from a diverse, experienced team of advisers who cover the necessary range of specialities required for all aspects of the Company's business, and also has a number of beneficial collaborative relationships with both clinicians and clinical centres. In particular, the Pipeline Agreement with the ICT, provides a strong working relationship with a world-recognised oncology research institute and access to future pipeline opportunities.
For more information on the Company please visit: www.incanthera.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the